The Danish, Finnish, Norwegian, Swedish and Icelandic lymphoma trials network, best known for the Nordic mantle cell lymphoma regimen.
The Nordic Lymphoma Group coordinates investigator-initiated lymphoma trials and registries across the Nordic countries, which share population registries that make long-term follow-up unusually complete. Its MCL2 and MCL3 trials established the Nordic regimen of intensified cytarabine-containing induction with rituximab and autologous transplant for younger patients with mantle cell lymphoma. NLG working groups cover aggressive, indolent, T-cell and Hodgkin lymphomas and collaborate with HOVON, the German groups, LYSA and IELSG. The group rotates its chair among the member countries.
Led NOVA and RUBY, the trials that established niraparib maintenance in ovarian cancer and dostarlimab in advanced endometrial cancer.
Helsinki oncologist who chairs the Nordic Lymphoma Group, the cooperative network that runs lymphoma trials and guidelines across the Nordic countries.
Shares HOVON, Monoclonal antibodies, Diffuse large B-cell lymphoma, Cytotoxic chemotherapy and the tag cooperative-group.
Shares International Extranodal Lymphoma Study Group, Hodgkin lymphoma, Monoclonal antibodies, Diffuse large B-cell lymphoma and the tag cooperative-group.
Shares HOVON, Chronic lymphocytic leukaemia and the tag cooperative-group.
Shares Hodgkin lymphoma, Cytotoxic chemotherapy and the tag cooperative-group.
Shares Chronic lymphocytic leukaemia and the tag cooperative-group.
Shares Hodgkin lymphoma and the tag cooperative-group.
Shares Cytotoxic chemotherapy and the tag cooperative-group.
Shares Cytotoxic chemotherapy and the tag cooperative-group.